78 related articles for article (PubMed ID: 12584283)
1. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
[TBL] [Abstract][Full Text] [Related]
2. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study.
Guida B; Cataldi M; Riccio E; Grumetto L; Pota A; Borrelli S; Memoli A; Barbato F; Argentino G; Salerno G; Memoli B
PLoS One; 2013; 8(8):e73558. PubMed ID: 24015307
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.
Wüthrich RP; Chonchol M; Covic A; Gaillard S; Chong E; Tumlin JA
Clin J Am Soc Nephrol; 2013 Feb; 8(2):280-9. PubMed ID: 23124782
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.
Ossareh S
Int J Nephrol Renovasc Dis; 2014; 7():161-8. PubMed ID: 24855385
[TBL] [Abstract][Full Text] [Related]
5. Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.
Nachankar A; Katyal A; Bansal N; Bishnoi A
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35803612
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature.
Cataldo E; Columbano V; Nielsen L; Gendrot L; Covella B; Piccoli GB
BMC Nephrol; 2018 Jul; 19(1):155. PubMed ID: 29966512
[TBL] [Abstract][Full Text] [Related]
7. Lessons of the month: Over-the-counter antacids causing hypercalcaemia: The emergence of calcium-alkali syndrome.
Maarouf A; Jones S
Clin Med (Lond); 2020 Jul; 20(4):e129-e130. PubMed ID: 32675162
[TBL] [Abstract][Full Text] [Related]
8. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
[TBL] [Abstract][Full Text] [Related]
9. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
Block GA; Spiegel DM; Ehrlich J; Mehta R; Lindbergh J; Dreisbach A; Raggi P
Kidney Int; 2005 Oct; 68(4):1815-24. PubMed ID: 16164659
[TBL] [Abstract][Full Text] [Related]
10. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer.
Raggi P; Bommer J; Chertow GM
J Heart Valve Dis; 2004 Jan; 13(1):134-41. PubMed ID: 14765851
[TBL] [Abstract][Full Text] [Related]
11. Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches.
Anand A; Aoyagi H
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241191
[TBL] [Abstract][Full Text] [Related]
12. The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials.
Phannajit J; Wonghakaeo N; Takkavatakarn K; Asawavichienjinda T; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
J Nephrol; 2022 Mar; 35(2):473-491. PubMed ID: 34061337
[TBL] [Abstract][Full Text] [Related]
13. Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins.
Laville SM; Massy ZA; Kamel S; Chillon JM; Choukroun G; Liabeuf S
Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33530404
[TBL] [Abstract][Full Text] [Related]
14. A High Throughput Isolation Method for Phosphate-Accumulating Organisms.
Anand A; Aoyagi H
Sci Rep; 2019 Dec; 9(1):18083. PubMed ID: 31792245
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
16. Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?
Strózecki P; Ostrowski J; Majczynska I; Sulikowska B; Odrowaz-Sypniewska G; Stefanska A; Manitius J
EJIFCC; 2005 Dec; 16(4):100-102. PubMed ID: 29899684
[No Abstract] [Full Text] [Related]
17. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
18. Design and baseline characteristics of the LANDMARK study.
Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
